Literature DB >> 30215682

ESCAT: a step in the right direction.

A J Silver1, J L Warner2.   

Abstract

Mesh:

Year:  2018        PMID: 30215682      PMCID: PMC6887682          DOI: 10.1093/annonc/mdy409

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Authors:  Susumu Kobayashi; Titus J Boggon; Tajhal Dayaram; Pasi A Jänne; Olivier Kocher; Matthew Meyerson; Bruce E Johnson; Michael J Eck; Daniel G Tenen; Balázs Halmos
Journal:  N Engl J Med       Date:  2005-02-24       Impact factor: 91.245

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

Authors:  J Mateo; D Chakravarty; R Dienstmann; S Jezdic; A Gonzalez-Perez; N Lopez-Bigas; C K Y Ng; P L Bedard; G Tortora; J-Y Douillard; E M Van Allen; N Schultz; C Swanton; F André; L Pusztai
Journal:  Ann Oncol       Date:  2018-09-01       Impact factor: 32.976

Review 4.  Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Authors:  Catherine B Meador; Christine M Micheel; Mia A Levy; Christine M Lovly; Leora Horn; Jeremy L Warner; Douglas B Johnson; Zhongming Zhao; Ingrid A Anderson; Jeffrey A Sosman; Cindy L Vnencak-Jones; Kimberly B Dahlman; William Pao
Journal:  Clin Cancer Res       Date:  2014-03-05       Impact factor: 12.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.